Targeting mTOR Signaling Can Prevent the Progression of FSGS

Mammalian target of rapamycin (mTOR) signaling is involved in a variety of kidney diseases. Clinical trials administering mTOR inhibitors to patients with FSGS, a prototypic podocyte disease, led to conflicting results, ranging from remission to deterioration of kidney function. Here, we combined co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Am Soc Nephrol
Autores principales: Zschiedrich, Stefan, Bork, Tillmann, Liang, Wei, Wanner, Nicola, Eulenbruch, Kristina, Munder, Stefan, Hartleben, Björn, Kretz, Oliver, Gerber, Simon, Simons, Matias, Viau, Amandine, Burtin, Martine, Wei, Changli, Reiser, Jochen, Herbach, Nadja, Rastaldi, Maria-Pia, Cohen, Clemens D, Tharaux, Pierre-Louis, Terzi, Fabiola, Walz, Gerd, Gödel, Markus, Huber, Tobias B
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Nephrology 2017
Materias:
Basic Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5491276/
https://ncbi.nlm.nih.gov/pubmed/28270414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016050519
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares